Go to content
UR Home

Endocrine immune-related adverse events in patients with metastatic renal and urothelial cancer treated with immune checkpoint-inhibitors

URN to cite this document:
DOI to cite this document:
Oppolzer, Immanuel Augustin ; Riester, Josef ; Büttner, Roland ; Burger, Maximilian ; Schnabel, Marco Julius
[img]License: Creative Commons Attribution 4.0
PDF - Published Version
Date of publication of this fulltext: 09 Jun 2023 05:57

This publication is part of the DEAL contract with Springer.


Purpose To evaluate the incidence, diagnosis and treatment of immune-related adverse events (e-irAE) of checkpoint inhibition (ICI) in metastatic urothelial carcinoma (mUC) and metastatic renal cell carcinoma (mRCC). Methods A retrospective, single-center study was conducted to identify a cohort that received ICI for mUC or mRCC. e-irAE were classified according to the CTCAE V.5.0. Patients ...


Owner only: item control page
  1. Homepage UR

University Library

Publication Server


Publishing: oa@ur.de
0941 943 -4239 or -69394

Dissertations: dissertationen@ur.de
0941 943 -3904

Research data: datahub@ur.de
0941 943 -5707

Contact persons